Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial

Mahamadou A. Thera, Ogobara K. Doumbo, Drissa Coulibaly, Dapa A. Diallo, Abdoulaye K. Kone, Ando B. Guindo, Karim Traore, Alassane Dicko, Issaka Sagara, Mahamadou S. Sissoko, Mounirou Baby, Mady Sissoko, Issa Diarra, Amadou Niangaly, Amagana Dolo, Modibo Daou, Sory I. Diawara, D. Gray Heppner, V. Ann Stewart, Evelina AngovElke S. Bergmann-Leitner, David E. Lanar, Sheetij Dutta, Lorraine Soisson, Carter L. Diggs, Amanda Leach, Alex Owusu, Marie Claude Dubois, Joe Cohen, Jason N. Nixon, Aric Gregson, Shannon L. Takala, Kirsten E. Lyke, Christopher V. Plowe

    Research output: Contribution to journalArticle

    Abstract

    Background. The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA-1-based blood-stage malaria vaccine FMP2.1/ AS02A in adults exposed to seasonal malaria. Methodology/Principal Findings. A phase 1 double Wind randomized controlled dose escalation trial was conductected in Bandiagara, Mall, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. The malaria vaccine FMP2.1/AS02A is a recombinant protein (FMP2.1) based on apical membrane antigen-1 (AMA-1) from the 3D7 clone of P. falciparum, adjuvanted with AS02A. The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert). Sixty healthy, malaria-experienced adults aged 18-55 y were recruited into 2 cohorts and randomized to receive either a half dose or full dose of the malaria vaccine (FMP2.1 25 μg/A502A 0.25 ml. or FMP2.1 50 μg/AS02a 0.5 ml) or rabies vaccine given in 3 doses at 0, 1 and 2 mo, and were followed for 1 y. Solicited symptoms were assessed for 7 d and unsolicited symptoms for 30 d after each vaccination. Sewious adverse events were assessed throughout the study. Titers of anti-AMA-1 antibodies were measured by ELISA and p. falciparum growth inhibition assays were performed on sera collected at pre- and post-vaccination time points. Transient local pain and swelling were common and more frequent in both malaria vaccine dosage groups than in the comparator group. Anti-AMA-1 antibodies increased significantly in both malaria vaccine groups, peaking at nearly 5-fold and more than 6-foid higher than baseline in the half-dose and full-dose groups, respectively. Conclusion/Significance. The FMP2.1/AS02A vaccine had a good safety profile, was well-talerated, and was highly immunogenic in malaria-exposed adults, This malaria vaccine is being evaluated in Phase 1 and 2 trials in children at this site.

    Original languageEnglish
    Article numbere1465
    Pages (from-to)1-11
    Number of pages11
    JournalPLoS One
    Volume3
    Issue number1
    DOIs
    Publication statusPublished - 2008

      Fingerprint

    Cite this

    Thera, M. A., Doumbo, O. K., Coulibaly, D., Diallo, D. A., Kone, A. K., Guindo, A. B., ... Plowe, C. V. (2008). Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: Results of a phase 1 randomized controlled trial. PLoS One, 3(1), 1-11. [e1465]. https://doi.org/10.1371/journal.pone.0001465